Read by QxMD icon Read


Natalia Ruiz-Negrón, Jyothi Menon, Jordan B King, Junjie Ma, Brandon K Bellows
BACKGROUND: Neuropathic pain significantly reduces an individual's quality of life and places a significant economic burden on society. As such, many cost-effectiveness analyses (CEAs) have been published for treatments available for neuropathic pain. OBJECTIVES: The primary objective of this systematic review was to provide a detailed summary of the estimates of cost-effectiveness from published CEAs comparing available treatments for neuropathic pain. The secondary objectives were to identify the key drivers of cost-effectiveness and to assess the quality of published CEAs in neuropathic pain...
January 14, 2019: PharmacoEconomics
Istvan M Majer, Jean-Gabriel Castaigne, Stephen Palmer, Lucy DeCosta, Marco Campioni
BACKGROUND AND OBJECTIVES: In economic evaluations in oncology, adjusted survival should be generated if imbalances in prognostic/predictive factors across treatment arms are present. To date, no formal guidance has been developed regarding how such adjustments should be made. We compared various covariate-adjusted survival modeling approaches, as applied to the ENDEAVOR trial in multiple myeloma that assessed carfilzomib plus dexamethasone (Cd) versus bortezomib plus dexamethasone (Vd)...
January 5, 2019: PharmacoEconomics
Gian Luca Di Tanna, Anna Bychenkova, Frank O'Neill, Heidi S Wirtz, Paul Miller, Briain Ó Hartaigh, Gary Globe
BACKGROUND: Heart failure (HF) is a well-recognized public health concern and imposes high economic and societal costs. Decision analytic models exist for evaluating the economic ramifications associated with HF. Despite this, studies that appraise these modelling approaches for augmenting best-practice decisions remain scarce. OBJECTIVE: Our objective was to conduct a systematic literature review (SLR) of published economic models for the management of HF and describe their general and methodological features...
December 31, 2018: PharmacoEconomics
Holly Guy, Vicki Laskier, Mark Fisher, W Richey Neuman, Iwona Bucior, Steven Deitelzweig, Alexander T Cohen
BACKGROUND: Studies show that the risk of venous thromboembolism (VTE) continues post-discharge in nonsurgical patients with acute medical illness. Betrixaban is the first anticoagulant approved in the United States (US) for VTE prophylaxis extending beyond hospitalization. OBJECTIVE: The aim was to establish whether betrixaban for VTE prophylaxis in nonsurgical patients with acute medical illness at risk of VTE in the US is cost-effective compared with enoxaparin...
December 21, 2018: PharmacoEconomics
Aureliano Paolo Finch, Patricia van Velzen, Gerben Ter Riet, Peter J Sterk, Jan M Prins, Judith E Bosmans
BACKGROUND: Most patients with mild to severe chronic obstructive pulmonary disease (COPD) experience exacerbations, which are also associated with increased healthcare costs. Despite limited evidence of antibiotics' benefits for exacerbations in outpatients, antibiotics are frequently prescribed. The aim of this study was to investigate whether doxycycline added to prednisolone is cost-effective compared to placebo plus prednisolone for the treatment of COPD acute exacerbations. METHODS: An economic evaluation from the societal perspective was performed alongside a 2-year randomised trial in 301 COPD patients in the Netherlands...
December 19, 2018: PharmacoEconomics
Bunchai Chongmelaxme, Pochamana Phisalprapa, Ratree Manthaisong, Piyameth Dilokthornsakul, Nathorn Chaiyakunapruk
Weight Reduction is Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand.
December 13, 2018: PharmacoEconomics
Shijie Ren, Hazel Squires, Emma Hock, Eva Kaltenthaler, Andrew Rawdin, Constantine Alifrangis
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme) of pembrolizumab (Keytruda® ) to submit evidence of its clinical and cost effectiveness for the treatment of locally advanced or metastatic urothelial cancer where cisplatin is unsuitable. The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG)...
December 13, 2018: PharmacoEconomics
Frederick W Thielen, Nasuh C Büyükkaramikli, Rob Riemsma, Debra Fayter, Nigel Armstrong, Ching-Yun Wei, Vanesa Huertas Carrera, Kate Misso, Gill Worthy, Jos Kleijnen, Isaac Corro Ramos
The National Institute for Health and Care Excellence (NICE), as part of the institute's single technology appraisal (STA) process, invited the company that makes obinutuzumab (Roche Products Limited) to submit evidence of the clinical and cost effectiveness of the drug in combination with chemotherapy, with or without obinutuzumab as maintenance therapy for adult patients with untreated, advanced follicular lymphoma (FL) in the UK. Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Erasmus University Rotterdam, was commissioned to act as the Evidence Review Group (ERG)...
December 13, 2018: PharmacoEconomics
Asrul Akmal Shafie, Annushiah Vasan Thakumar, Ching Jou Lim, Nan Luo, Kim Rand-Hendriksen, Faridah Aryani Md Yusof
OBJECTIVES: The aim of this study was to develop an EQ-5D-5L value set reflecting the health preferences of the Malaysian adult population. METHODS: Respondents were sampled with quotas for urbanicity, gender, age, and ethnicity to ensure representativeness of the Malaysian population. The study was conducted using a standardized protocol involving the EuroQol Valuation Technology (EQ-VT) computer-assisted interview system. Respondents were administered ten composite time trade-off (C-TTO) tasks and seven discrete choice experiment (DCE) tasks...
December 11, 2018: PharmacoEconomics
Brent A Metfessel, Michelle D Mentel, Amy Phanel, Mary Ann Dimartino, Mureen Allen, Samuel Ho
BACKGROUND: Opioid use and misuse are urgent health issues. Previous studies suggest that opioid use increases healthcare resource use but severity adjustment is lacking. OBJECTIVE: The objective of this study was to evaluate the severity-adjusted cost difference between opioid users and non-users among patients with conservatively managed degenerative joint disease of the spine within a large commercial health plan population in the United States. METHODS: A retrospective observational study was performed using a national commercial database covering 531,819 patients aged 18-64 years with non-surgically managed cervical or lumbar degenerative spine disease during 2015-6...
December 6, 2018: PharmacoEconomics
Min Huang, M Catherine Pietanza, Ayman Samkari, James Pellissier, Thomas Burke, Sheenu Chandwani, Fansen Kong, A Simon Pickard
OBJECTIVES: Pembrolizumab monotherapy showed significantly longer overall survival and fewer treatment-related adverse events compared to chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1)-positive tumors in the first-line setting in KEYNOTE (KN)-024 and in those previously treated in KN010. The objective of this analysis was to assess the benefit-risk of pembrolizumab in terms of quality-adjusted survival amongst patients in these trials...
December 4, 2018: PharmacoEconomics
Nicolas Krucien, Nathalie Pelletier-Fleury, Amiram Gafni
BACKGROUND: The final outcome of any resource allocation decision in healthcare cannot be determined in advance. Thus, decision makers, in deciding which new program to implement (or not), need to accommodate the uncertainty of different potential outcomes (i.e., change in both health and costs) that can occur, the size and nature (i.e., 'bad' or 'good') of these outcomes, and how they are being valued. Using the decision-making plane, which explicitly incorporates opportunity costs and relaxes the assumptions of perfect divisibility and constant returns to scale of the cost-effectiveness plane, all the potential outcomes of each resource allocation decision can be described...
November 30, 2018: PharmacoEconomics
Holly Guy, Lydia Walder, Mark Fisher
OBJECTIVES: The aim was to evaluate the cost-effectiveness of niraparib compared with routine surveillance (RS), olaparib and rucaparib for the maintenance treatment of patients with recurrent ovarian cancer (OC). METHODS: A decision-analytic model estimated the cost per quality-adjusted life-year (QALY) gained for niraparib versus RS, olaparib, and rucaparib from a US payer perspective. The model considered recurrent OC patients with or without germline BRCA mutations (gBRCAmut and non-gBRCAmut), who were responsive to their last platinum-based chemotherapy regimen...
November 27, 2018: PharmacoEconomics
Linda M de Vries, Pieter H M van Baal, Werner B F Brouwer
There has been considerable debate on the extent to which future costs should be included in cost-effectiveness analyses of health technologies. In this article, we summarize the theoretical debates and empirical research in this area and highlight the conclusions that can be drawn for current practice. For future related and future unrelated medical costs, the literature suggests that inclusion is required to obtain optimal outcomes from available resources. This conclusion does not depend on the perspective adopted by the decision maker...
November 26, 2018: PharmacoEconomics
Chun-Ru Chien, Daniel M Geynisman, Bumyang Kim, Ying Xu, Ya-Chen Tina Shih
BACKGROUND: The economic burden of renal cell carcinoma (RCC) had been reported to be significant in a previous review published in 2011. OBJECTIVE: The objective of this study was to perform an updated review by synthesizing economic studies related to the treatment of RCC that have been published since the previous review. METHODS: We performed a literature search in PubMed, EMBASE, and the Cochrane Library, covering English-language studies published between June 2010 and August 2018...
November 23, 2018: PharmacoEconomics
Rhiannon Tudor Edwards
No abstract text is available yet for this article.
November 22, 2018: PharmacoEconomics
Becky Pennington, Shije Ren, Samantha Barton, Mariana Bacelar, Steven J Edwards
As part of its Single Technology Appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer (EUSA Pharma) of dinutuximab beta (Qarziba® ) to submit evidence of its clinical and cost effectiveness for treating neuroblastoma. The BMJ Technology Assessment Group (BMJ-TAG) was commissioned to act as the Evidence Review Group (ERG), reviewing the submission from the company. The Decision Support Unit (DSU) was commissioned to review additional evidence submitted by the company and to undertake further analyses...
November 22, 2018: PharmacoEconomics
Lindsay Claxton, Joanne O'Connor, Nerys Woolacott, Kath Wright, Robert Hodgson
The title of the article should read.
November 22, 2018: PharmacoEconomics
Bunchai Chongmelaxme, Pochamana Phisalprapa, Ratree Sawangjit, Piyameth Dilokthornsakul, Nathorn Chaiyakunapruk
INTRODUCTION: This study evaluated lifetime liver-related clinical outcomes, costs of treatment, and the cost-effectiveness of treatment options for non-alcoholic fatty liver disease (NAFLD) in Thailand. METHODS: A cost-utility analysis using a lifetime Markov model was conducted among Thai patients with NAFLD, from a societal perspective. Pioglitazone, vitamin E, a weight reduction program, and usual care were investigated, with the outcomes of interest being the number of cirrhosis and hepatocellular carcinoma (HCC) cases, life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and the incremental cost-effectiveness ratios (ICERs)...
November 15, 2018: PharmacoEconomics
Bram L T Ramaekers, Rob Riemsma, Sabine Grimm, Debra Fayter, Sohan Deshpande, Nigel Armstrong, Willem Witlox, Xavier Pouwels, Steven Duffy, Gill Worthy, Jos Kleijnen, Manuela A Joore
The National Institute for Health and Care Excellence (NICE) invited Teva, the company manufacturing arsenic trioxide (ATO; tradename Trisenox® ), to submit evidence for the clinical and cost effectiveness of ATO for untreated and relapsed or refractory acute promyelocytic leukaemia (APL). Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Maastricht University Medical Center, was commissioned as the independent Evidence Review Group (ERG). This paper presents a summary of the company submission (CS), the ERG's critical review of the clinical and cost effectiveness evidence in the CS, key methodological considerations and the development of the NICE guidance by the Appraisal Committee (AC)...
November 14, 2018: PharmacoEconomics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"